Life Biosciences announced an upcoming presentation of interim first-in-human Phase 1 data for ER-100, an epigenetic restoration candidate for glaucoma.
On October 1, 2026, Life Biosciences announced plans to present interim data from its ongoing first-in-human Phase 1 trial of ER-100 at the American Academy of Ophthalmology 2026 meeting.
The scheduled presentation marks a significant milestone for experimental epigenetic interventions targeting age-related conditions. This Phase 1 study focuses primarily on establishing the safety and tolerability of the clinical candidate. The trial includes additional endpoints intended to measure changes in visual function. This evaluation represents a necessary step toward understanding whether attempting to reset cellular patterns can yield measurable clinical outcomes safely.
This clinical trial and the upcoming interim data presentation are conducted in humans.
Life Biosciences describes ER-100 as the first clinical candidate to emerge from its specialized Epigenetic Restoration platform. The company states that this therapeutic approach relies on the controlled expression of three specific factors, which are OCT4, SOX2, and KLF4. This specific combination is often abbreviated as OSK. The intended mechanism is to reset established epigenetic patterns within the tissue and induce a more youthful gene-expression profile.
The company is currently developing this candidate for two specific and challenging optic neuropathies. These targeted conditions are open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. Both of these disorders involve underlying damage to retinal ganglion cells, which are vital neurons that physically connect the eye to the brain. According to the company, these specific retinal ganglion cells lack the natural ability to regenerate once they are damaged.
Open-angle glaucoma is explicitly framed by the company as a chronic neurodegenerative disease. Life Biosciences notes that disease progression can often continue despite standard clinical treatment. They also point out that some patients with open-angle glaucoma maintain normal intraocular pressure while still experiencing worsening symptoms. This highlights the clinical interest in developing alternative interventions that address the underlying cellular damage directly.
Non-arteritic anterior ischemic optic neuropathy presents as sudden and painless vision loss. The company associates this condition with insufficient blood flow to the optic nerve. According to the public announcement, there are currently no approved medical treatments for this specific condition. This total lack of existing therapies underscores the significant unmet medical need that the company hopes to address with its new candidate.
Sharon Rosenzweig-Lipson, PhD, the chief scientific officer at Life Biosciences, detailed the specific aim of the ongoing study. She stated that the company is testing whether ER-100 can successfully restore damaged retinal ganglion cells to a more youthful state. This approach intends to address the root cellular damage rather than simply slowing the rate of vision loss. It is critical to recognize that this represents the company hypothesis rather than a demonstrated clinical effect.
The Phase 1 clinical trial, officially identified as NCT07290244, began patient enrollment in the first quarter of 2026. The rapid progression from the start of the study to an interim data presentation suggests early milestones are being tracked closely. However, the available public announcement does not supply detailed enrollment figures, specific cohort sizes, or trial duration metrics. It also omits crucial context regarding the exact dose levels being tested in the human subjects.
The scheduled presentation will take place on October 8, 2026, during the Eyecelerator event at the medical meeting in New Orleans. The session, titled Glaucoma Digital, is scheduled for 2:10 p.m. Central Time. Rosenzweig-Lipson will serve as the primary presenter for the company. This event will provide the medical community with the first public look at the interim safety data.
Readers monitoring emerging longevity technology should clearly understand the strict limits of this early announcement. The October 1 press release functions purely as a notice of planned data disclosure. It does not report any actual clinical results, adverse events, or early efficacy estimates. The true clinical profile of the candidate will remain entirely unknown until the data are formally presented and subjected to critical scientific review.
The language used by the company heavily emphasizes terms like cellular rejuvenation and epigenetic resetting. While these terms accurately describe the intended biological mechanism, they do not serve as proof of clinical success. The announcement itself does not establish that the candidate actually rejuvenates human retinal cells. Furthermore, it provides no evidence yet that the therapy restores vision or reverses glaucoma-related damage in human patients.
Evaluating such early-stage clinical announcements requires careful attention to the trial phase and its primary endpoints. Because this is a Phase 1 study, its fundamental purpose is to determine if the intervention is safe for human administration. While visual function assessments are included as additional endpoints, early phase trials are rarely powered to prove definitive clinical efficacy. Therefore, observers must interpret any reported functional improvements as preliminary data requiring further study.
Individuals evaluating longevity clinical trials should look for specific details during the upcoming October presentation. Important missing details include the number of participants evaluated, the safety events observed, and the length of the follow-up period. It will also be critical to see which specific visual-function measures were utilized by the researchers. Finally, observers should note whether the interim results are reported separately for the two distinct optic neuropathies being studied.
To validate these early concepts, researchers must present the complete interim safety outcomes and eventually advance to properly controlled Phase 2 efficacy trials.
Navigating interim clinical data for cellular therapies requires separating actual safety measurements from long-term assumptions, which is why AgeAmaze provides objective breakdowns of early trial announcements. We clarify overstated claims around biological age, supplements, peptides and emerging therapies to help research-minded adults understand what early-phase studies actually prove. Read the research
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
